靶向苗勒管抑制物质II型受体的放射性标记抗体:卵巢癌诊疗一体化的新工具
研究开发了靶向苗勒管抑制物质II型受体(MISRII)的小鼠单克隆抗体16F12,并在腹腔MISRII阳性AN3CA子宫内膜癌移植瘤小鼠模型中评估了177Lu或213Bi标记的16F12用于常规腹腔放射免疫治疗(IP-RIT)与短暂腹腔放射免疫治疗(BIP-RIT)的效果,以及89Zr-16F12用于PET成像的可行性。结果显示BIP-RIT的肿瘤/血液摄取比显著高于IP-RIT,213Bi-16F12在BIP-RIT中优于177Lu-16F12,而177Lu-16F12的血液学毒性更明显。作者认为放射性标记16F12可能成为小体积卵巢腹膜癌病诊疗一体化的新工具。
要点
- BIP-RIT的肿瘤/血液摄取比显著高于IP-RIT(213Bi与177Lu-16F12均如此)。
- IP-RIT中177Lu-16F12延缓肿瘤生长略优于213Bi-16F12,而BIP-RIT中213Bi-16F12更优。
- 177Lu-16F12的血液学毒性较213Bi-16F12更明显。
核心结论
- 放射性标记16F12可能成为小体积卵巢腹膜癌病的诊疗一体化新工具。
- 作者认为,基于213Bi-16F12的BIP-RIT可作为减瘤手术后立即开始的辅助治疗选择,用于特定患者。
- 抗MISRII单克隆抗体目前正在开展首次人体研究,使放射性标记抗MISRII单克隆抗体成为临床现实的诊疗一体化选项。
研究设计与样本
- 临床前研究,使用小鼠单克隆抗体16F12靶向MISRII。
- 在移植后第13天,对腹腔内MISRII阳性AN3CA子宫内膜癌细胞移植瘤小鼠进行治疗。
- 常规IP-RIT使用10 MBq 177Lu-16F12或12.9 MBq 213Bi-16F12。
- BIP-RIT使用50 MBq 177Lu-16F12或37 MBq 213Bi-16F12,注射后30分钟冲洗腹腔以去除未结合放射性。
- 进行177Lu-和213Bi-16F12的生物分布测定用于剂量评估,并监测血液学毒性。
主要发现
- 16F12单克隆抗体治疗和成像的放射性标记均令人满意。
- IP-RIT中,177Lu-16F12延缓肿瘤生长略优于213Bi-16F12。
- BIP-RIT中,213Bi-16F12优于177Lu-16F12。
- 生物分布分析显示,BIP-RIT的肿瘤/血液摄取比显著高于IP-RIT(213Bi-和177Lu-16F12均如此)。
- 177Lu-16F12的血液学毒性较213Bi-16F12更明显。
关键数值与推荐
- IP-RIT治疗剂量:10 MBq 177Lu-16F12或12.9 MBq 213Bi-16F12。
- BIP-RIT治疗剂量:50 MBq 177Lu-16F12或37 MBq 213Bi-16F12,注射后30分钟冲洗腹腔。
临床怎么用
- 原文未据此给出临床推荐。
- 作者认为,基于213Bi-16F12的BIP-RIT可作为减瘤手术后立即开始的辅助治疗选择,用于特定患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We have developed the 16F12 mouse monoclonal antibody (mAb), which targets the Müllerian-inhibiting substance receptor, type II (MISRII), expressed by ovarian tumors. Here, we assessed in preclinical models the possibility of using radiolabeled 16F12 in a theranostic approach for small-volume ovarian peritoneal carcinomatosis, such as after cytoreductive surgery. Methods: DOTA-, DTPA- or deferoxamine mesylate-conjugated 16F12 mAb was radiolabeled with β-particle (177Lu) or α-particle (213Bi) emitters for therapeutic use and with 89Zr for PET imaging. On the 13th postxenograft day, mice bearing intraperitoneal MISRII-positive AN3CA endometrial carcinoma cell xenografts were treated by conventional intraperitoneal radioimmunotherapy (IP-RIT) with 10 MBq of 177Lu-16F12 or 12.9 MBq of 213Bi-16F12 or by brief intraperitoneal radioimmunotherapy (BIP-RIT) using 50 MBq of 177Lu-16F12 or 37 MBq of 213Bi-16F12. For BIP-RIT, 30 min after injection of the radiolabeled mAbs, the peritoneal cavity was washed to remove the unbound radioactivity. The biodistribution of 177Lu- and 213Bi-16F12 mAbs was determined and then used for dose assessment. Hematologic toxicity was also monitored. Results: The 16F12 mAb was satisfactorily radiolabeled for both therapy and imaging. IP-RIT with 177Lu-16F12 was slightly more efficient in delaying tumor growth than IP-RIT with 213Bi-16F12. Conversely, 213Bi-16F12 was more efficient than 177Lu-16F12 in BIP-RIT. The biodistribution analysis showed that the tumor-to-blood uptake ratio was significantly higher with BIP-RIT than with IP-RIT for both 213Bi- and 177Lu-16F12. Hematologic toxicity was more pronounced with 177Lu-16F12 than with 213Bi-16F12. SPECT/CT images (after BIP-RIT with 177Lu-16F12) and PET/CT images (after injection of 89Zr-16F12 in the tail vein) showed focal uptake at the tumor site. Conclusion: Radiolabeled 16F12 could represent a new theranostic tool for small-volume ovarian peritoneal carcinomatosis. Specifically, 213Bi-16F12-based BIP-RIT could be proposed to selected patients as an alternative adjuvant treatment immediately after cytoreductive surgery. An anti-MISRII mAb is currently being used in a first-in-human study, thus making radiolabeled anti-MISRII mAbs a realistic theranostic option for the clinic.
引用
- Deshayes E, Ladjohounlou R, Le Fur P, et al. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. J Nucl Med. 2018. PMID: 29674421. doi:10.2967/jnumed.118.208611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。